|
|
|
|
|
|
|
|
|
01.10.26 - 08:01
|
Roche presents new data at EURETINA, highlighting Vabysmo′s real-world effectiveness and safety across major retinal conditions (GlobeNewswire EN)
|
|
|
Basel, 1 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the VOYAGER study evaluating the effectiveness, durability and safety of Vabysmo® (faricimab) in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO).1-3 Across all study cohorts, results confirm the real-world effectiveness of Vabysmo in line with Phase III trial results, with vision gains and robust anatomical improvements in untreated eyes and stable or improved vision with improved anatomical outcomes in previously treated eyes.1-3...
|
|
|
|
|
|
|
|
|
|
|
30.09.26 - 11:42
|
Roche Hold (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Roche mit einem Kursziel von 340 Franken auf "Hold" belassen. Entgegen der Marktreaktion sieht der Analyst Emmanuel Papadakis den jährlichen Pharmatag der Schweizer geringfügig ......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29.09.26 - 16:54
|
Beyond Cellular Models: Longevica Capitalizes on World′s Largest In Vivo Longevity Study to Form Star-Studded Advisory Board and Unlock Human Health-and-Lifespan Pipeline (Business Wire)
|
|
|
Led by newly appointed CEO Dr. Prasun Mishra (ex-Genentech, Roche, NIH), Longevica leverages data from 16,000+ test subjects and 1,033 compounds to power AI discovery, drug repurposing, pet therapies, and novel therapeutic development to extend human and pet health and lifespan.SAN FRANCISCO & NEW YORK--(BUSINESS WIRE)--$ARKG #AI--Longevica Therapeutics, a biotechnology company bridging the translation gap between empirical geroscience and human therapeutics, today announced the formation of its Scientific Advisory Board (SAB). Featuring globally recognized leaders spanning cell signaling, computational phenomics, multi-omics, quantitative pharmacology, medicinal chemistry, clinical trial execution, and biopharma venture capital, the multidisciplinary assembly marks Longevica's operational pivot from foundational discovery and data generation to clinical execution, drug development, and strategic alliance building.
While traditional biotech approaches have historically relied on simplified cell lines, sh...
|
|
|
29.09.26 - 12:48
|
Roche Underperform (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Roche mit einem Kursziel von 230 Franken auf "Underperform" belassen. Der diesjährige Pharmatag der Schweizer habe keine Überraschungen geboten, schrieb Michael Leuchten am ......
|
|
|
29.09.26 - 11:45
|
Roche Hold (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Roche mit einem Kursziel von 340 Franken auf "Hold" belassen. Dies schrieb Analyst Emmanuel Papadakis in seiner am Dienstag vorliegenden Auswertung der wöchentlichen Verschreibungszahlen./ag/ckVeröffentlichung ......
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
